Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
02 Mai 2018 - 1:00PM
Business Wire
Foundation Medicine, Inc. (NASDAQ:FMI) today announced a
comprehensive gene expression profiling (GEP) program to support
precision oncology clinical research and development. This
initiative, which provides a natural complement to Foundation
Medicine’s comprehensive genomic profiling (CGP) suite of molecular
information tests, further enhances support for the Company’s
biopharma partners in the efficient identification of known and
novel genomic and expression-based biomarkers of response for
investigational and approved personalized cancer therapies,
including new and existing cancer immunotherapies.
“In order to maximize the potential of personalized cancer
therapy, we need a comprehensive biomarker strategy that includes
not only tumor mutational changes and signatures but robust
readouts of gene expression, requiring deep expertise in next
generation DNA and RNA sequencing,” said Vincent Miller, M.D.,
chief medical officer at Foundation Medicine. “The initiation of a
GEP program at Foundation Medicine is a natural extension of our
work in redefining genomic biomarkers for precision oncology
treatments, and we are excited to combine this expertise to help
our biopharma partners optimize their clinical research development
programs. Bringing together Foundation Medicine’s unique
combination of comprehensive genomic sequencing and gene expression
could help determine which therapeutic approach is right for each
patient and each tumor type as we develop new classes of
personalized cancer treatments with our biopharma partners.”
CGP of individual tumors is critical to advancing precision
oncology. Through its suite of CGP assays, Foundation Medicine has
pioneered the measurement of quantitative genomic biomarkers,
including microsatellite instability (MSI) and tumor mutational
burden (TMB), which are informing immunotherapy research, clinical
development and treatment decisions.
Building on Foundation Medicine’s existing DNA and RNA
sequencing platforms, GEP has the potential to provide insights
into gene expression signatures that may serve as predictive
biomarkers of immunotherapy response. For example, measuring
expression of genes tied to tumor-infiltrating lymphocytes, T-cell
proliferation, and T-cell receptor diversity have all been
associated with response to different types of oncology treatments.
Under this program, Foundation Medicine will initially provide
research-use only GEP for its biopharma partners. Such
collaborations help integrate novel genomic biomarkers into
clinical practice and optimize clinical trial design and drug
development. Together this may pave new paths for the
biopharmaceutical industry to expand the potential of precision
oncology.
About Foundation MedicineFoundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding
of the genomic changes that contribute to each patient's unique
cancer. The company offers a full suite of comprehensive genomic
profiling assays to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies,
immunotherapies and clinical trials. Foundation Medicine’s
molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers
and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit
http://www.FoundationMedicine.com or follow Foundation Medicine on
Twitter (@FoundationATCG).
Foundation Medicine® is a trademark of Foundation Medicine,
Inc.
Cautionary Note Regarding Forward-Looking Statements for
Foundation MedicineThis press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding the ability of gene expression profiling to identify
novel genomic and expression-based biomarkers of response; the
ability of CGP to advance prevision oncology or improve patient
outcomes; and the benefits of Foundation Medicine’s gene expression
profiling program to biopharma partners, including optimizing
clinical research development programs and drug development. All
such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risk that the gene expression profiling program does not
proceed or does not meet its objectives; gene expression profiling
is not an effective method of identifying genomic and
expression-based biomarkers; the utility of gene expression
profiling for biopharma partners does not materialize; and the
risks described under the caption "Risk Factors" in Foundation
Medicine's Annual Report on Form 10-K for the year ended December
31, 2017, which is on file with the Securities and Exchange
Commission, as well as other risks detailed in Foundation
Medicine's subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Foundation Medicine undertakes no duty to
update this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180502005328/en/
Foundation Medicine, Inc.Media Contact:Lee-Ann Murphy,
617-245-3077pr@foundationmedicine.comorInvestor
Contact:Kimberly Brown,
617-418-2215ir@foundationmedicine.com
Foundation Medicine, Inc. (NASDAQ:FMI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024